Tara Anderson, PA
Staff Affiliate - YNHHCards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAbout
Copy Link
Titles
Staff Affiliate - YNHH
Departments & Organizations
- All Institutions
- Multiple Myeloma and Gammopathies Program
- Yale Medicine
- Yale New Haven Health System
Education & Training
- PA
- University of Toledo
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Tara Anderson's published research.
Natalia Neparidze, MD
Noffar Bar, MD
Sabrina Browning, MD
Terri Parker, MD
Stuart Seropian, MD
Ashita Talsania, MRCP, MBBS, MD
Publications
2025
Target antigen density may impact clinical response in patients with relapsed/refractory multiple myeloma undergoing treatment with elotuzumab and belantamab mafodotin
Albano F, Browning S, Li F, Bar N, Parker T, Anderson T, Stevens E, VanOudenhove J, Matthews M, Gorshein E, Haldas J, Talsania A, Sabbath K, Seropian S, Halene S, Perna F, Neparidze N. Target antigen density may impact clinical response in patients with relapsed/refractory multiple myeloma undergoing treatment with elotuzumab and belantamab mafodotin. Blood 2025, 146: 7578. DOI: 10.1182/blood-2025-7578.Peer-Reviewed Original ResearchConceptsBCMA-targeted therapyBelantamab mafodotinPhase I partRelapsed/refractory myelomaClinical responseStable diseasePartial responseCombination therapyMedian ageMultiple myelomaImmune profileT cellsBone marrowB cellsDay 1PD1+ T cellsAssociated with clinical responseMedian age of patientsCD19+ B cellsFlow cytometryI partCombination of elotuzumabImmune combination therapyInferior clinical responsePhase Ib/II trial
2024
Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma
Browning S, Li F, Theprungsirikul P, Parker T, Bar N, Giri S, Anderson T, Stevens E, Gorshein E, Sabbath K, Wei C, Ali S, Witt D, Persico J, Talsania A, Rahmat L, Kidwai W, Legare R, LaSala J, Austin M, Neparidze N. Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma. Blood 2024, 144: 7831. DOI: 10.1182/blood-2024-204150.Peer-Reviewed Original ResearchConceptsRelapsed/Refractory Multiple MyelomaInternational Myeloma Working GroupAdverse eventsGlobal health statusFunctional scalesMultiple symptom scalesPartial responseProteasome inhibitorsMultiple myelomaHealth statusEastern Cooperative Oncology Group performance statusClinical trialsMonoclonal antibody targeting CD38Median progression free survivalRelapsed/refractory multiple myeloma patientsIntroduction of novel therapiesHealth-related quality of lifeClinical response assessmentDaratumumab-based regimensProgression free survivalInfusion-related reactionsLines of therapyPatient-reported quality of life outcomesMean fatigue scoreHealth-related qualityP-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM)
Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.Peer-Reviewed Original ResearchAssociations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.Peer-Reviewed Original ResearchCitationsAltmetricConceptsChimeric antigen receptor T cellsRelapsed/Refractory Multiple MyelomaT cell fitnessHigh-risk cytogeneticsCytokine release syndromeNon-respondersExtramedullary diseaseT cellsPeripheral blood prior to treatmentInternational Myeloma Working Group criteriaNR groupBlood prior to treatmentBispecific T-cell engagerMedian follow-up timeMedian prior linesT-cell therapyPost-treatment follow-upT-cell engagersT cell influxT-cell %Working Group criteriaYale Cancer CenterMann-Whitney U testResponse to disease progressionIdecabtagene vicleucel
Academic Achievements & Community Involvement
Copy Link
Clinical Care
Copy Link
Overview
Clinical Specialties
Medical Oncology; Hematology & Oncology
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileGet In Touch
Copy Link
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.